Non-invasive assessment of tissue iron overload.

In recent years, there has been increasing interest in non-invasive iron measurement, especially of the liver and heart, in patients with iron overload. Serum ferritin still remains an essential monitoring parameter in intervals between liver iron measurements; however, confounding factors such as inflammation, chelation treatment changes and the specific disease have to be taken into account. Liver iron measurements can now routinely be performed in clinical applications either by quantitative magnetic resonance imaging (MRI) using the transverse magnetic relaxation rate R(2) or R(2)* (1/T(2)*) or by biomagnetic liver susceptometry. For iron measurements in the heart, the single-breathhold multi-echo MRI-R(2)* method has become a standard modality and is now applied in clinical settings beyond research studies. In other tissues like the pancreas, pituitary, and brain, different MRI methods are employed, but their clinical benefit has yet to be proven.

[1]  Greg Brown,et al.  Observational study of iron overload as assessed by magnetic resonance imaging in an adult population of transfusion‐dependent patients with β thalassaemia: significant association between low cardiac T2* < 10 ms and cardiac events , 2010, Internal medicine journal.

[2]  E. Alexopoulou,et al.  Assessment of iron distribution between liver, spleen, pancreas, bone marrow, and myocardium by means of R2 relaxometry with MRI in patients with β‐thalassemia major , 2009, Journal of magnetic resonance imaging : JMRI.

[3]  T. Coates,et al.  Spleen R2 and R2* in iron‐overloaded patients with sickle cell disease and thalassemia major , 2009, Journal of magnetic resonance imaging : JMRI.

[4]  M. Cappellini,et al.  Correlation of liver iron concentration determined by R2 magnetic resonance imaging with serum ferritin in patients with thalassemia intermedia , 2008, Haematologica.

[5]  T. Coates,et al.  Longitudinal analysis of heart and liver iron in thalassemia major. , 2008, Blood.

[6]  T. Coates,et al.  Magnetic resonance detection of kidney iron deposition in sickle cell disease: A marker of chronic hemolysis , 2008, Journal of magnetic resonance imaging : JMRI.

[7]  D. Pennell,et al.  One‐stop measurement of iron deposition in the anterior pituitary, liver, and heart in thalassemia patients , 2008, Journal of magnetic resonance imaging : JMRI.

[8]  T. Coates,et al.  Onset of cardiac iron loading in pediatric patients with thalassemia major , 2008, Haematologica.

[9]  W. Au,et al.  A T2* magnetic resonance imaging study of pancreatic iron overload in thalassemia major , 2008, Haematologica.

[10]  E. Vichinsky,et al.  Serum ferritin underestimates liver iron concentration in transfusion independent thalassemia patients as compared to regularly transfused thalassemia and sickle cell patients , 2007, Pediatric blood & cancer.

[11]  A. Karantanas,et al.  Bone marrow changes in beta-thalassemia major: quantitative MR imaging findings and correlation with iron stores , 2007, European Radiology.

[12]  Nathalie Boddaert,et al.  Selective iron chelation in Friedreich ataxia: biologic and clinical implications. , 2007, Blood.

[13]  L. Astrakas,et al.  Liver, bone marrow, pancreas and pituitary gland iron overload in young and adult thalassemic patients: a T2 relaxometry study , 2007, European Radiology.

[14]  D. Farrell,et al.  Liver Iron Susceptometry , 2007 .

[15]  A. Piga,et al.  Monitoring Long‐Term Efficacy of Iron Chelation Treatment with Biomagnetic Liver Susceptometry , 2005, Annals of the New York Academy of Sciences.

[16]  D. Tsiapras,et al.  A comparison of magnetic resonance imaging and cardiac biopsy in the evaluation of heart iron overload in patients with β‐thalassemia major , 2005, European journal of haematology.

[17]  N. Gourtsoyiannis,et al.  Adrenal glands in beta-thalassemia major: magnetic resonance (MR) imaging features and correlation with iron stores , 2005, European Radiology.

[18]  T. Coates,et al.  MRI R2 and R2* mapping accurately estimates hepatic iron concentration in transfusion-dependent thalassemia and sickle cell disease patients. , 2005, Blood.

[19]  Thomas D. Coates,et al.  Cardiac Iron Determines Cardiac T2*, T2, and T1 in the Gerbil Model of Iron Cardiomyopathy , 2005, Circulation.

[20]  Huaqing Zhao,et al.  1/T2 and magnetic susceptibility measurements in a gerbil cardiac iron overload model. , 2005, Radiology.

[21]  T. S. St. Pierre,et al.  Noninvasive measurement and imaging of liver iron concentrations using proton magnetic resonance. , 2005, Blood.

[22]  Yu-Chung N. Cheng,et al.  Susceptibility weighted imaging (SWI) , 2004, Zeitschrift fur medizinische Physik.

[23]  D. Pennell,et al.  A single breath‐hold multiecho T2* cardiovascular magnetic resonance technique for diagnosis of myocardial iron overload , 2003, Journal of magnetic resonance imaging : JMRI.

[24]  H. Eiskjaer,et al.  Evaluation of myocardial iron by magnetic resonance imaging during iron chelation therapy with deferrioxamine: indication of close relation between myocardial iron content and chelatable iron pool. , 2003, Blood.

[25]  H. Cario,et al.  Insulin sensitivity and β-cell secretion in thalassaemia major with secondary haemochromatosis: assessment by oral glucose tolerance test , 2003, European Journal of Pediatrics.

[26]  D N Firmin,et al.  Cardiovascular T2-star (T2*) magnetic resonance for the early diagnosis of myocardial iron overload. , 2001, European heart journal.

[27]  F. Jensen,et al.  Indirect evidence for the potential ability of magnetic resonance imaging to evaluate the myocardial iron content in patients with transfusional iron overload , 2001, Magnetic Resonance Materials in Physics, Biology and Medicine.

[28]  M. Kami,et al.  Hepatic iron concentration and total body iron stores in thalassemia major. , 2000, The New England journal of medicine.

[29]  T. S. St. Pierre,et al.  Quantitative mapping of transverse relaxivity (1/T(2)) in hepatic iron overload: a single spin-echo imaging methodology. , 2000, Magnetic resonance imaging.

[30]  R. Fischer,et al.  Assessment of iron stores in children with transfusion siderosis by biomagnetic liver susceptometry , 1999, American journal of hematology.

[31]  G. Brittenham,et al.  Iron-chelating therapy and the treatment of thalassemia. , 1997, Blood.

[32]  C. McLaren,et al.  Efficacy of deferoxamine in preventing complications of iron overload in patients with thalassemia major. , 1994, The New England journal of medicine.

[33]  K. Batts,et al.  Liver biopsy diagnosis of homozygous hemochromatosis: a diagnostic algorithm. , 1993, Mayo Clinic proceedings.

[34]  J. Hazell,et al.  Desferrioxamine ototoxicity: evaluation of risk factors in thalassaemic patients and guidelines for safe dosage , 1989, British journal of haematology.

[35]  W. Stremmel,et al.  Survival and Causes of Death in Hemochromatosis , 1988 .

[36]  J. Tripp,et al.  Magnetic-susceptibility measurement of human iron stores. , 1982, The New England journal of medicine.

[37]  J. H. Tripp,et al.  Magnetic measurement of human iron stores , 1980 .

[38]  W. Roberts,et al.  Iron in the heart. Etiology and clinical significance. , 1971, The American journal of medicine.

[39]  Roger Williams,et al.  Variability in hepatic iron concentration in percutaneous needle biopsy specimens from patients with transfusional hemosiderosis. , 2005, American journal of clinical pathology.

[40]  A. Cnaan,et al.  Survival and complications in patients with thalassemia major treated with transfusion and deferoxamine. , 2004, Haematologica.

[41]  G. Brittenham,et al.  Noninvasive measurement of iron: report of an NIDDK workshop. , 2003, Blood.

[42]  Peter A. Rinck,et al.  Magnetic Resonance in Medicine , 1993 .

[43]  W. Stremmel,et al.  Survival and causes of death in hemochromatosis. Observations in 163 patients. , 1988, Annals of the New York Academy of Sciences.